Trial Profile
A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms FINCH 4
- Sponsors Galapagos NV; Gilead Sciences
- 15 Nov 2023 Results of pooled analysis from DARWIN 1-3 (NCT01888874, NCT01894516, NCT02065700) and FINCH 1-4 (NCT02889796, NCT02873936, NCT02886728, NCT03025308) trials assessing the incidence of malignancies excluding nonmelanoma skin cancer (NMSC), NMSC, MACE and venous thromboembolism (VTE) in patients treated with FIL200 or FIL100, presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis from 7 clinical trials NCT01888874, NCT01894516 NCT02889796, NCT02873936, NCT02886728, NCT02065700 & NCT03025308, presented at the ACR Convergence 2023.
- 15 Nov 2023 Results evaluating long-term efficacy of two doses of FIL in clinically relevant patient populations presented at the ACR Convergence 2023